🤚 The Open-Palm Biological Invoice
The premise is simple, the implications are not: a $101 million XPRIZE competition is asking scientists to reverse aging by 10 to 20 years in living humans aged 50-80, and the finalists are about to be announced. Peter Diamandis — who co-founded XPRIZE and has never met a moonshot he didn’t want to fund — posed the downstream question nobody in longevity circles wants to touch: if we actually crack age reversal, what happens to taxes?
It’s a fair question. The entire architecture of modern governance — Social Security, Medicare, pension systems, retirement ages, estate taxes — is built on the assumption that people have the decency to die within a predictable actuarial window. XPRIZE Healthspan is trying to shatter that window with a scientific sledgehammer, and the IRS hasn’t even started drafting the memo.
The competition launched in 2023 with over 600 registered teams from 58 countries. The Top 40 healthspan teams have already been selected as Milestone 1 winners, and in July 2026 — weeks from now — XPRIZE will announce the 10 finalists who’ll receive a second $10 million milestone prize and enter full human clinical trials running through 2029. The grand prize winner in 2030 takes home up to $81 million.
👐 The Two-Handed Pharmaceutical Reckoning
The teams still in the running represent a staggering diversity of approaches: biologics, devices, drugs, lifestyle interventions, and personalized monitoring. But the entry generating the most headlines belongs to David Sinclair, the Harvard geneticist who has built a career on the controversial premise that aging is a disease — and diseases can be cured.
Sinclair’s approach is chemical reprogramming: an oral drug cocktail designed to epigenetically restore cells to a younger state across the entire body. His team’s formulation, codenamed SL-100, combines vitamins, approved medications, and experimental molecules. Previous iterations of this research used ingredients like forskolin (a supplement), tranylcypromine (an antidepressant), and laduviglusib (an experimental chemical) — a combination that reads like a pharmacy had a nervous breakdown.
“What we’re aiming to do is to epigenetically restore the animal and eventually the person,” Sinclair stated, with the confidence of a man who has been saying this for two decades and is now within striking distance of a nine-figure prize.
The catch — because there is always a catch in longevity research — is that other researchers have reported whole-animal chemical rejuvenation attempts proved toxic at high concentrations and ineffective at low doses. The therapeutic window between “it works” and “it kills you” remains, scientifically speaking, narrow. No published human results exist yet. The field is simultaneously closer than ever to a breakthrough and exactly as far from one as it has always been.
🌿 The Gentle Awakening
Now, about those taxes. The economic implications of adding 10-20 healthy years to human lifespan aren’t just significant — they’re civilization-restructuring. According to AARP research, adults aged 50 and older already account for $12.5 trillion in annual economic activity, projected to grow through 2060. A Fortune analysis from April 2026 warned that America is “not ready for its own longevity crisis,” with roughly 80% of households with adults over 60 lacking resources to cover long-term care or weather financial emergencies.
And that’s the current system, where people age normally. Introduce actual age reversal, and every assumption breaks:
- Social Security was designed when life expectancy was 63. If people routinely live to 110 with the body of a 60-year-old, the trust fund doesn’t need reform — it needs a funeral.
- Retirement as a concept dissolves. Why stop working at 65 if your biology says you’re 45? Career arcs would span decades longer, with implications for hiring, seniority, and every “OK Boomer” joke ever written.
- Estate taxes become existentially confused. If Grandma never dies, inheritance is just a very long-term savings account with occasional holiday obligations.
- Healthcare costs might actually decrease — the most expensive years of medical care are the final ones, and healthy aging could compress morbidity into a much shorter window.
Morgan Stanley has already published research on how longevity is “reshaping economies, industries, and financial planning.” But their models assume incremental gains — an extra five years here, better chronic disease management there. Nobody on Wall Street has modeled what happens when a Harvard geneticist’s pill takes 20 years off your pancreas.
👑 The Crown Verdict
The XPRIZE Healthspan competition is the rare intersection of hard science and existential philosophy. The teams competing aren’t just trying to win $81 million — they’re attempting to fundamentally alter humanity’s relationship with time. And Diamandis, ever the optimist with the budget to back it up, sees the downstream disruption not as a problem but as an opportunity: longer lives mean longer productive years, more innovation cycles, more compound growth of human capital.
The tax question, though, is where the velvet gloves come off. Governments built fiscal systems around mortality tables. If those tables are wrong — not by a few years, but by decades — then the social contract itself needs renegotiation. And if history is any guide, governments will begin adapting to the longevity revolution approximately 15 years after it becomes unavoidable, which means we should expect congressional hearings on age reversal taxation sometime around 2055, when the senators themselves will be biologically younger than their interns.
The finalists will be announced in weeks. The human trials begin this year. And somewhere in a Harvard lab, David Sinclair is mixing vitamins and antidepressants into a cocktail that might just break the tax code.
Inspired by The End of Aging and Taxes? | MOONSHOTS by Peter H. Diamandis.
Your mortality assumption is showing. Amortize wisely.